The effect of paclitaxel on the radiosensitivity of gynecological tumor cells - PubMed (original) (raw)
Comparative Study
doi: 10.1007/BF03039438.
Affiliations
- PMID: 9176559
- DOI: 10.1007/BF03039438
Comparative Study
The effect of paclitaxel on the radiosensitivity of gynecological tumor cells
M Rave-Fränk et al. Strahlenther Onkol. 1997 May.
Abstract
Background: Paclitaxel, a natural product from Taxus brevifolia, is a microtubule stabilizing agent, which has been shown to block different cells in the G2/M phase of the cell cycle and consequently, to modulate their radioresponsiveness. Our aim was to test the cytotoxic and radiosensitizing potential of paclitaxel, with respect to different gynecological tumors with varying radiosensitivities.
Material and method: We performed clonogenic assays and flow cytometry on 2 cell lines, MCF-7 (breast) and CaSki (cervix) cells, and on 2 primary ovarian tumor samples (OC-I and OC-II). The cells were irradiated with 200 kV X-rays, radiation doses of up to 8 Gy were applied either as single doses or in 2 Gy fractions. Paclitaxel concentrations varied from 0.07 to 700 nM, incubation times varied from 3 to 120 h.
Results: Paclitaxel alone changed the cell cycle distribution of the cells tested and was cytotoxic in a time and concentration dependent manner. When combined with radiation, most schedules resulted in additive effects of the combined treatments. However, for MCF-7 cells, when 7 nM paclitaxel, applied 24 h before irradiation, were combined with fractionated irradiation a supra-additive effect with a SER of 1.2 was found. For CaSki cells, under comparable conditions the SER was 1.13 but the effects were not statistically significant.
Conclusion: Under specific conditions, paclitaxel exerted a weak radiosensitizing effect on breast and cervical carcinoma cells. A therapeutic gain may be possible on the basis of an optimal paclitaxel/radiation scheduling.
Similar articles
- Effects of paclitaxel in combination with radiation on human head and neck cancer cells (ZMK-1), cervical squamous cell carcinoma (CaSki), and breast adenocarcinoma cells (MCF-7).
Pradier O, Rave-Fränk M, Schmidberger H, Bömecke M, Lehmann J, Meden H, Hess CF. Pradier O, et al. J Cancer Res Clin Oncol. 1999;125(1):20-7. doi: 10.1007/s004320050237. J Cancer Res Clin Oncol. 1999. PMID: 10037273 - Cytotoxicity and cell-cycle effects of paclitaxel when used as a single agent and in combination with ionizing radiation.
Gupta N, Hu LJ, Deen DF. Gupta N, et al. Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):885-95. doi: 10.1016/s0360-3016(96)00535-4. Int J Radiat Oncol Biol Phys. 1997. PMID: 9128966 - [Radiosensitization of paclitaxel combined with radiation on nasopharygneal carcinoma cells (CNE-I) in vitro].
Yuan ZY, Yang WZ, Jin J, Gao L, Liu XF, Xu GZ. Yuan ZY, et al. Zhonghua Zhong Liu Za Zhi. 2007 Sep;29(9):649-52. Zhonghua Zhong Liu Za Zhi. 2007. PMID: 18246791 Chinese. - [Combined effect of Paclitaxel and ionizing radiation. Experimental data of in-vitro and in-vivo models].
Rübe C, Hampel G, Schuck A, Willich N. Rübe C, et al. Strahlenther Onkol. 1996 May;172 Suppl 1:2-5. Strahlenther Onkol. 1996. PMID: 8633269 Review. German. No abstract available. - Paclitaxel (Taxol): a success story with valuable lessons for natural product drug discovery and development.
Cragg GM. Cragg GM. Med Res Rev. 1998 Sep;18(5):315-31. doi: 10.1002/(sici)1098-1128(199809)18:5<315::aid-med3>3.0.co;2-w. Med Res Rev. 1998. PMID: 9735872 Review.
Cited by
- Comparison of two platinum-containing chemotherapy regimens in the treatment of advanced cervical cancer with concurrent chemoradiotherapy.
Chen YY, Huang YT. Chen YY, et al. Ann Med. 2024 Dec;56(1):2371008. doi: 10.1080/07853890.2024.2371008. Epub 2024 Aug 2. Ann Med. 2024. PMID: 39092860 Free PMC article. - Pharmacotherapy options for locally advanced and advanced cervical cancer.
Dueñas-González A, Cetina L, Coronel J, Martínez-Baños D. Dueñas-González A, et al. Drugs. 2010 Mar 5;70(4):403-32. doi: 10.2165/11534370-000000000-00000. Drugs. 2010. PMID: 20205484 Review. - Radiosensitizers in cervical cancer. Cisplatin and beyond.
Candelaria M, Garcia-Arias A, Cetina L, Dueñas-Gonzalez A. Candelaria M, et al. Radiat Oncol. 2006 May 8;1:15. doi: 10.1186/1748-717X-1-15. Radiat Oncol. 2006. PMID: 16722549 Free PMC article. - Radiochemotherapy with paclitaxel: synchronization effects and the role of p53.
Wenz F, Greiner S, Germa F, Mayer K, Latz D, Weber KJ. Wenz F, et al. Strahlenther Onkol. 1999 Oct;175 Suppl 3:2-6. doi: 10.1007/BF03215919. Strahlenther Onkol. 1999. PMID: 10554637
References
- Gynecol Oncol. 1993 Feb;48(2):252-8 - PubMed
- Int J Radiat Oncol Biol Phys. 1992;22(3):613-7 - PubMed
- Cancer. 1995 May 1;75(9):2262-8 - PubMed
- Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):559-64 - PubMed
- Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1381-9 - PubMed